AMN 082 dihydrochloride

Pricing Availability   Qty
说明: Selective mGlu7 agonist
化学名: N,N'-Bis(diphenylmethyl)-1,2-ethanediamine dihydrochloride
纯度: ≥99% (HPLC)
说明书
引用文献 (3)
评论 (1)
文献 (3)

生物活性 for AMN 082 dihydrochloride

AMN 082 dihydrochloride is a the first selective mGlu7 agonist. Potently inhibits cAMP accumulation and stimulates GTPγS binding in recombinant cells and on membranes expressing mGlu7 (EC50 = 64 - 290 nM). Selective over other mGluR subtypes and selected ionotropic glutamate receptors up to 10 μM. Acts via a novel allosteric site and is orally active and brain penetrant. Reduces haloperidol-induced catalepsy in rats.

View important information regarding the usage of AMN 082 dihydrochloride.

化合物库 for AMN 082 dihydrochloride

AMN 082 dihydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for AMN 082 dihydrochloride

分子量 465.45
公式 C28H28N2.2HCl
储存 Desiccate at +4°C
纯度 ≥99% (HPLC)
CAS Number 97075-46-2
PubChem ID 11698390
InChI Key YRQCDCNQANSUPB-UHFFFAOYSA-N
Smiles Cl.Cl.C(CNC(C1=CC=CC=C1)C1=CC=CC=C1)NC(C1=CC=CC=C1)C1=CC=CC=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for AMN 082 dihydrochloride

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 46.55 100
water 0.93 2 温和加热

制备储备液 for AMN 082 dihydrochloride

以下数据基于产品分子量 465.45。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 2.15 mL 10.74 mL 21.48 mL
5 mM 0.43 mL 2.15 mL 4.3 mL
10 mM 0.21 mL 1.07 mL 2.15 mL
50 mM 0.04 mL 0.21 mL 0.43 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for AMN 082 dihydrochloride

分析证书/产品说明书
选择另一批次:

参考文献 for AMN 082 dihydrochloride

参考文献是支持产品生物活性的出版物。

Greco et al (2010) Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J.Pharmacol.Exp.Ther. 332 1064 PMID: 19940105

Flor et al (2005) AMN082, the first selective mGluR7 agonist: activation of receptor signaling via an allosteric site in the transmembrane domain modulates stress parameters in vivo. Neuropharmacology 49 244

Mitsukawa et al (2005) A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc.Natl.Acad.Sci.USA 102 18712


If you know of a relevant reference for AMN 082 dihydrochloride, please let us know.

关键词: AMN 082 dihydrochloride, AMN 082 dihydrochloride supplier, selective, mGlu7, mGluR7, agonists, mGlur, Group, III, Receptors, Glutamate, Metabotropic, AMN082, dihydrochloride, (Metabotropic), 2385, Tocris Bioscience

3 篇 AMN 082 dihydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。 AMN 082 dihydrochloride 的部分引用包括:

Jantas et al (2018) New evidences for a role of mGluR7 in astrocyte survival: Possible implications for neuroprotection. Neuropharmacology 141 223 PMID: 30170084

Shao et al (2019) Activating metabotropic glutamate receptor-7 attenuates visceral hypersensitivity in neonatal maternally separated rats. Int J Mol Med 43 761 PMID: 30569115

Broadstock et al (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165 1034 PMID: 21627638


您是否知道使用了 Tocris AMN 082 dihydrochloride 的优秀论文? 请告知我们.

AMN 082 dihydrochloride 的评论

平均评分: 4 (Based on 1 Review.)

5 星
0%
4 星
100%
3 星
0%
2 星
0%
1 星
0%

Have you used AMN 082 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Test of potential modulation of 5HT-1B receptor effects.
By Sergiy Sylantyev on 12/10/2023
分析类型: In Vitro
种属: Mouse
细胞系/组织: Arcuate nucleus

AMN 082 was used to test a (potential) impact of metabotropic glutamate receptors on the effect of 5HT-1B receptors on neurotransmitter vesicle release in interneuronal synapse. Picture: membrane capacitance fluctuation of living neuron after series of electrical stimuli delivered to acute neural tissue. Left: control. Right: activation of metabotropic glutamate receptors (with 1 μM CHPG, 1 μM (RS)-3,5-DHPG and 1 μM AMN 082), GABA-B receptors and ACh receptors does not show a significant effect. Grey traces: individual recordings; red: averaged trace.

PMID: 37827445
review image

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.